| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Molecular and Cellular Biology, May 2007, p. 3708-3715, Vol. 27, No. 10
0270-7306/07/$08.00+0 doi:10.1128/MCB.01838-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Graduate Program in Immunobiology,1 Programs in Signal Transduction and Stem Cells and Regeneration, Burnham Institute for Medical Research, La Jolla, California 92037,2 Department of Veterinary and Biomedical Sciences, The Pennsylvania State University, University Park, Pennsylvania 168023
Received 28 September 2006/ Returned for modification 18 December 2006/ Accepted 27 February 2007
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The Friend virus susceptibility locus 2, Fv2, encodes a naturally occurring, N-terminally truncated form of the Stk receptor tyrosine kinase, the murine homologue of the human Ron receptor, called Sf-Stk (25). The expression of Sf-Stk in erythroid progenitor cells is driven by an internal promoter, and the translation of this transcript generates a protein that lacks the extracellular ligand binding domain of full-length Stk, while retaining the transmembrane and kinase domains. C57BL/6 mice harbor mutations in the internal promoter in the gene encoding Stk, resulting in reduced Sf-Stk expression and Friend virus resistance. Sf-Stk is required for Epo-independent colony formation induced by Friend virus infection. Exogenous expression of Sf-Stk rescues the Epo-independent growth of Friend virus-infected erythroid progenitor cells in vitro (8) and renders C57BL/6 mice susceptible to Friend erythroleukemia in vivo (25).
The viral glycoprotein gp55, from the spleen focus forming virus, interacts with the erythropoietin receptor (EpoR) (18) and Sf-Stk (23), and this signaling complex drives the Epo-independent expansion of Friend virus-infected cells. We have shown previously that the kinase domain and Grb2 binding site of Sf-Stk are required for this response to Friend virus infection (8) and that a Grb2/Gab2 complex downstream of Sf-Stk mediates the growth of primary erythroid progenitor cells infected in vitro with Friend virus (33). Recent studies have demonstrated that mice harboring a human EpoR knocked in to the murine locus (which fails to interact with gp55) develop leukemia, but not the characteristic polycythemia, in response to Friend virus infection (40). Taken together, these data suggest that signaling through Sf-Stk plays a central role in the polyclonal expansion of infected progenitor cells, whereas EpoR regulates the differentiation of these cells.
The activation of Stat5 by EpoR has been extensively studied and plays a key role in the differentiation of erythroid progenitor cells in response to Epo. However, while Epo and gp55 both lead to the activation of Stat5 in erythroid cells, nuclear translocation and DNA binding of Stat5 are not observed in response to gp55, suggesting that Stat5 may not play an essential role in the transmission of the cell growth signals in gp55-induced erythroleukemia cells (37). Furthermore, mice with a targeted deletion in Stat5 develop erythroleukemia in response to the polycythemia-inducing strain of Friend virus (FVP), but without the characteristic development of polycythemia (40), indicating that like EpoR, Stat5 is required for the differentiation, but not the expansion, of Friend virus target cells (40).
Stat1 and Stat3 are also activated by EpoR and have been suggested to play distinct roles in erythropoiesis (15, 16), although the mechanism of tyrosine phosphorylation of Stat1 and Stat3 by EpoR is distinct from that of Stat5 (12, 14). Mice harboring a targeted deletion in Stat1 exhibit overall reductions in erythroid progenitor cells (11); however, the role of Stat3 in erythropoiesis in vivo has not been elucidated. Constitutive activation of Stat1 and Stat3 has been demonstrated in primary erythroleukemic cells (13) and cell lines infected with spleen focus forming virus (24). Taken together, these data suggest potential roles for Stat1 and Stat3 in regulating the aberrant growth of erythroid progenitor cells in Friend disease.
Here, we set out to determine the role of Stat3 in the progression of Friend erythroleukemia. We demonstrate that Stat3 is required for the Epo-independent growth of Friend virus-infected erythroid progenitor cells. Furthermore, we identified a novel Stat3 binding site in Gab2 which is required for this process, suggesting that the activation of Stat3 in Friend virus-infected cells is mediated by an Sf-Stk/Grb2/Gab2 signaling pathway. These studies highlight a critical role for Stat3 activation in the progression of Friend erythroleukemia and identify a novel mechanism for the activation of Stat3 downstream of tyrosine kinases. Interestingly, Gab2 is also required for the transformation of hematopoietic cells by BCR/Abl (29), which suggests that the observations described here could have broader implications for the function of Gab2 in various hematopoietic malignancies.
| MATERIALS AND METHODS |
|---|
|
|
|---|
DNA constructs. Gab1/2 chimeric molecules were obtained by three-way ligation. The primers used were 1S1, 5'-CGGGGTACCATGTATGATGTTCCTGATTATGCTAGCCTCAGCGGTGGTGAAGTGGTCTG-3'; 1S2, 5'-CCAACAGAAGAAGATCCTGTG-3'; 1S3, 5'-CATCCAGCTCATGACCGATC-3'; 1S4, 5'-AACCCAAACCTGTCCAGTGAAG-3'; 1AS1, 5'-CCGGAATTCTCATTTCACACTCTTCGCTGGCG-3'; 1AS2, 5'-ATTAAACCCACAGATGTCACAAATAC-3'; 1AS3, 5'-TGGTTTCGGTGGCCGAGGTG-3'; 1AS4, 5'-CATGGGAACATAATTCTCTTCAC-3'; 2S1, 5'-CGGGGTACCATGTATGATGTTCCTGATTATGCTAGCCTCAGCGGCGGCGGCGACGTGG-3'; 2S2, 5'-CAGGCTGAGGAGAGCACAG-3'; 2S3, 5'-AGTCAGGCAGAAACACCTCG-3'; 2S4, 5'-CAAAACCCAGTGTCTGCATCTC-3'; 2AS1, 5'-GCGGATCCTCTCATCACAGCTTG-3'; 2AS2, 5'-ATTGAAGCCACAGATCTGGCAG-3'; 2AS3, 5'-TGGCTTGGGGGGGCGGG-3'; and 2AS4, 5'-CATAGGGACATAGTTCTCTTCG-3'. Partial cDNA fragments of Gab1 and Gab2 were synthesized independently by PCRs with the appropriate primer pairs, digested with restriction enzymes, and inserted into the pcDNA3 vector. For each fragment, primer pairs were as follows: for CM1, Gab12-592 (1S1 and 1AS4) and Gab2588-676 (2S4 and 2AS1); for CM2, Gab12-348 (1S1 and 1AS3) and Gab2359-676 (2S3 and 2AS1); for CM3, Gab22-118 (1S1 and 1AS2) and Gab2120-676 (2S2 and 2AS1); for CM4, Gab22-119 (2S1 and 2AS2) and Gab1119-694 (1S2 and 1AS1); for CM5, Gab22-358 (2S1 and 2AS3) and Gab1349-694 (1S3 and 1AS1); and for CM6, Gab22-587 (2S1 and 2AS4) and Gab1593-694 (1S4 and 1AS1). For the purpose of ligation reactions, phosphate groups were added to the 5' end of the primers prior to PCRs. These oligonucleotides (250 pmol) were incubated with 10 U T4 polynucleotide kinase (Biolabs) and 1 mM ATP in a 25-µl reaction volume for 30 min at 37°C. The enzyme was deactivated by 10 min of incubation at 70°C.
MSCV-neo-myc/sf-stk, MSCV-neo-myc/sf-stk(Y429F), and MSCV-neo-myc/sf-stk(Y436F) were described previously (8). MSCV-neo-myc/sf-stk(KD) was produced by site-directed mutagenesis using the Stratagene QuikChange kit (Stratagene), following the manufacturer's protocol. Using MSCV-neo-myc/sf-stk as a template, the mutation was introduced with the oligonucleotide (sense) 5'-GCGTCCTAGACAAGGAATTCTTCAGTGTTCGCCAGCATC-3'.
The murine MSCV-neo-Gab2 and MSCV-neo-myc/sf-stk/Gab2 cDNAs were described previously (34). The QuikChange mutagenesis kit was used to mutate MSCV-neo-Gab2 and MSCV-neo-myc/sf-stk/Gab2 to MSCV-neo-Gab2(Y/F) and MSCV-neo-myc/sf-stk/Gab2(Y/F), respectively, by using the oligonucleotide (sense) 5'-CACCTCAGGAGTATCTCTTCTTGCACCAGTGCATAAGC-3'. The MSCV-neo-myc/sf-stk(KD)/Gab2 cDNA was introduced by site-directed mutagenesis (Stratagene QuikChange kit) following the manufacturer's protocol. The template was MSCV-neo-myc/sf-stk/Gab2, and the primer was (sense) 5'-CCACTGTGCCATCATGTCTCTGAGTCGG-3'.
The dominant negatives pRc CMV-Stat3(Y705F) and pRc CMV-Stat3(ZZ/VVV) (kind gifts of C. Horvath, Northwestern University) were excised from the pRc cytomegalovirus vector with NotI and ApaI and subcloned into MSCV-neo at the HpaI site to produce MSCV-neo-Stat3(Y705F) and MSCV-neo-Stat3(ZZ/VVV). Wild-type MSCV-neo-Stat3 was generated by site-directed mutagenesis (Stratagene QuikChange kit) following the manufacturer's protocol. The template was MSCV-neo-Stat3(Y705F) and the primer was (sense) 5'-ACCTTCCTACTGCGCTTCAG-3'.
Transient transfection. The 293T cell line was grown in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, penicillin-streptomycin, and L-glutamine. Cells were transiently transfected by the TransIT-293 transfection reagent (Mirus Corporation) by using 1 to 2 µg pEco and the appropriate murine stem cell virus (MSCV)-neo constructs (1 to 10 µg) at 37°C for 48 to 72 h prior to harvest of the viral supernatant. Protein expression from the various plasmids was verified by Western blot analysis.
In vitro infection and colony assay. For in vitro infection of bone marrow, cells were harvested from femurs and tibias of >6-week-old BALB/c, C57BL/6, or Gab2/ mice and washed in phosphate-buffered saline. Bone marrow was infected with viral supernatant from the transient transfections for 20 h as previously described (8). For Epo-independent colony analysis, total bone marrow cells from different strains of mice were harvested and incubated with supernatant from cells expressing FVP (derived from FP63 cells [Alan Bernstein, Mount Sinai Hospital, Toronto, Ontario, Canada]) or Dulbecco's modified Eagle's medium (10% fetal bovine serum, penicillin-streptomycin, and L-glutamine) on ice for 1 h, as previously described (34). Cells were added to MethoCult medium M3234 (StemCell Technologies), along with 2.5 ng interleukin-3 (IL-3) (PeproTech), in triplicate with or without 1 U/ml Epo (R&D Systems). Cultures were incubated for 2 to 8 days in 5% CO2 at 37°C. Erythroid colonies (erythroid burst-forming unit [BFU-E] and CFU-E) were visualized by acid-benzidine staining as previously described (8).
Antibodies, immunoprecipitation, and Western blotting. Mouse anti-Myc (1:1,000), rabbit anti-stat3 (1:1,000), and rabbit anti-phospho-stat3(Y705) (1:1,000) antibodies were purchased from Cell Signaling. Mouse anti-Gab1 was purchased from Santa Cruz. Rabbit anti-Gab2 and rabbit anti-phospho-stat3 (S727) antibodies were purchased from Upstate. Rabbit anti-ß-actin antibody was purchased from Sigma. 293T cells were transiently transfected with plasmids expressing the desired protein. Twenty-four hours after transfection, cells were lysed in lysis buffer (1% NP-40, 150 mM NaCl, 1 mM EDTA, 0.25% deoxycholate, 2 mM Na3VO4, 10 mM NaF, and 2 mM phenylmethylsulfonyl fluoride). After 15 min of centrifugation, the cleared cell lysates were incubated with the indicated antibodies and protein A (or G)-Sepharose at 4°C overnight. The immunoprecipitates were analyzed by reduced SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to a polyvinylidene difluoride membrane. The blots were incubated with the appropriate antibodies, and bands were detected with ECL (Amersham).
Flow cytometry analysis. Bone marrow cells were collected after in vitro infection, fixed with 2% paraformaldehyde for 10 min on ice, and analyzed by flow cytometry for green fluorescent protein (GFP) expression.
| RESULTS |
|---|
|
|
|---|
|
The Y194LHQ motif in Gab2 interacts with Stat3 and mediates tyrosine phosphorylation of Stat3 downstream of Stk. To determine whether Stat3 is downstream of Sf-Stk, we coexpressed Sf-Stk and Stat3 in 293 cells. Here, we demonstrate that Sf-Stk induces tyrosine phosphorylation of Stat3 in 293 cells and that this phosphorylation is dependent on Y436 (Fig. 2A). In addition, the expression of the Sf-Stk/Gab2 fusion, but not Sf-Stk/Gab1, enhanced tyrosine phosphorylation of Stat3 in these cells (Fig. 2B). Therefore, we tested the abilities of the Gab1/Gab2 fusion proteins to mediate Stat3 activation when coexpressed with Sf-Stk. Interestingly, the ability of Gab2 to enhance tyrosine phosphorylation of Stat3 in the presence of Sf-Stk mapped to the same region of Stat3 that was required for hematopoietic transformation in response to Friend virus infection (Fig. 2C).
|
|
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
In v-Eyk, the mutation of the receptor tyrosine kinase c-Eyk results in the presence of a YXXQ motif, a canonical Stat3 binding site (36), leading to the enhanced activation of Stat3 and cellular transformation (2). In addition, enhanced tyrosine phosphorylation of Stat3 has been associated with the mutation of the aspartic acid in the kinase domain of the Kit receptor tyrosine kinase; the activation of this pathway is required for its transforming ability (22), and the juxtamembrane mutations in the Kit receptor found in gastrointestinal stromal tumors have propensities similar to those of activate Stat proteins (5). However, while most tyrosine kinases activate the Stat3 signaling pathway, few contain a canonical Stat3 binding motif. Here we demonstrate, for the first time, a functional Stat3 binding motif in Gab2. The ability of receptor tyrosine kinases to recruit Gab2 through a Grb2-dependent mechanism suggests the possibility that a wide range of receptor tyrosine kinases could activate the Stat3 signaling pathway via a Grb2-/Gab2-dependent mechanism.
There is increasing evidence that the Grb2-/Gab2-dependent signaling pathway may also play a central role in transformation. Gab2 maps to 11q13-14, a region that is commonly amplified in breast cancer, that is found to be overexpressed in human breast cancer, and that potentiates breast carcinogenesis in mice induced by ErbB2 (1, 7). In addition, a Grb2/Gab2 signaling pathway is critical for leukemic transformation by BCR/Abl (30) and the inhibition of Gab2 with RNA interference inhibits colony formation by primary chronic myeloid leukemia cells (30). A Grb2 binding site also contributes to leukemogenesis induced by the Tel/Abl tyrosine kinase (20), and Gab2 mediates mast cell proliferation in response to the Kit receptor tyrosine kinase (39). Taken together, these observations indicate that Gab2 could be activated downstream of tyrosine kinases in hematopoietic cells and propagate signals required for the transforming activity of those kinases.
Gab2 is a large adaptor protein (related to the insulin receptor substrate family of adaptors) which transmits signals from a number of receptor tyrosine kinases and is recruited to active signaling complexes through two mechanisms: a polyproline-rich region that binds the N-terminal SH3 domain of Grb2 and a pleckstrin homology domain that is recruited to the membrane by phospholipids generated by PI3 kinase (10, 19). Two Shp-2 binding motifs and three p85 binding sites conserved in all Gab family members (Gab1, Gab2, and Gab3) have been shown to be critical for the activation of the Erk and PI3 kinase pathways, respectively. Accordingly, we found that the mutation of the Shp2 or p85 binding sites in Gab2 in the context of an Sf-Stk/Gab2 fusion protein reduced cellular transformation of primary erythroblasts in response to Friend virus (34). However, these signaling pathways were retained in an Sf-Stk/Gab1 fusion protein that failed to support the transformation of Friend virus-infected bone marrow cells, indicating that Gab2 must harbor unique functions which are not associated with the activation of Gab1 that are also required for transformation. Our data indicate that the recruitment and activation of Stat3 by Gab2 cooperate with signals generated by Shp2 and p85 and are required for the ability of Gab2 to mediate the transformation of primary hematopoietic cells downstream of the Stk receptor tyrosine kinase.
While the mechanism by which most receptor tyrosine kinases lead to the activation of the Stat3 signaling pathway is unclear, many studies have implicated Src family kinases in this process (9, 27, 35). Recent studies have demonstrated that (i) the hematopoietic cell kinase mediates the phosphorylation of Gab1 and Gab2 in multiple myeloma cells (26), (ii) Lyn and Syk are required for Gab2 tyrosine phosphorylation downstream of Fc
R1 (38), and (iii) granulocyte colony-stimulating factor-induced tyrosine phosphorylation of Gab2 is Lyn kinase dependent (41). We have shown here that the kinase activity is not required for the activation of Stat3 and the Epo-independent growth of Friend virus-infected cells in the context of an Sf-Stk/Gab2 fusion protein. This raises the intriguing possibility that the activation of Stat3 downstream of receptor tyrosine kinases, including Stk, could be mediated by the Src-dependent phosphorylation of Gab2, resulting in the recruitment and activation of Stat3. Indeed, our unpublished observations demonstrate a requirement for Src family kinases in the transformation of primary erythroblasts by Friend leukemia virus in vitro. However, our studies with the Lyn knockout mice did not reveal a critical role for the Lyn tyrosine kinase in the early stages of transformation in vivo (31).
In this study, we have identified a novel receptor tyrosine kinase/Grb2/Gab2/Stat3 signaling pathway required for the transformation of primary hematopoietic cells by using Friend erythroleukemia virus as a model system. Although the targeting of tyrosine kinases has become the first line of therapy in treating leukemia and other malignancies, the occurrence of drug resistance has highlighted the necessity for identifying multiple complementary targets for the successful treatment of these diseases. The identification of specific downstream signaling events that mediate transformation will aid in the elucidation of a new generation of targets for drug therapy. Our data indicate that blocking the ability of Gab2 to recruit and activate Stat3 may provide a novel target in the treatment of leukemia and possibly a wider range of human cancers.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
Published ahead of print on 12 March 2007. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Besser, D., J. Bromberg, J. Darnell, and H. Hanafusa. 1999. A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation. Mol. Cell. Biol. 19:1401-1409.
3. Bromberg, J., C. Horvath, D. Besser, W. Latham, and J. Darnell. 1998. Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. 18:2553-2558.
4. Bromberg, J., M. Wrzeszczynska, G. Devgan, Y. Zhao, R. Pestell, C. Albanese, and J. Darnell. 1999. Stat3 as an oncogene. Cell 98:295-303.[CrossRef][Medline]
5. Casteran, N., P. De Sepulveda, N. Beslu, M. Aoubala, S. Letard, E. Lecocq, R. Rottapel, and P. Dubreuil. 2003. Signal transduction by several KIT juxtamembrane domain mutations. Oncogene 22:4710-4722.[CrossRef][Medline]
6. Chiarle, R., W. J. Simmons, H. Cai, G. Dhall, A. Zamo, R. Raz, J. G. Karras, D. E. Levy, and G. Inghirami. 2005. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 11:623-629.[CrossRef][Medline]
7. Daly, R., H. Gu, J. Parmar, S. Malaney, R. Lyons, R. Kairouz, D. Head, S. Henshall, B. Neel, and R. Sutherland. 2002. The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer. Oncogene 21:5175-5181.[CrossRef][Medline]
8. Finkelstein, L. D., P. A. Ney, Q. P. Liu, R. F. Paulson, and P. H. Correll. 2002. Sf-Stk kinase activity and the Grb2 binding site are required for Epo-independent growth of primary erythroblasts infected with Friend virus. Oncogene 21:3562-3570.[CrossRef][Medline]
9. Garcia, R., T. Bowman, G. Niu, H. Yu, S. Minton, C. Muro-Cacho, C. Cox, R. Felcome, R. Fairclough, S. Parsons, A. Laudano, A. Gazit, A. Levitzki, A. Raker, and R. Jove. 2001. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20:2499-2513.[CrossRef][Medline]
10. Gu, H., and B. G. Neel. 2003. The Gab in signal transduction. Trends Cell Biol. 13:122.[CrossRef][Medline]
11. Halupa, A., M. Bailey, K. Huang, N. Iscove, D. Levy, and D. Barber. 2005. A novel role for Stat1 in regulating murine erythropoiesis: deletion of Stat1 results in overall reduction of erythroid progenitor cells and alters their distribution. Blood 105:552-561.
12. Haq, R., A. Halupa, B. Beattie, J. Mason, B. Zanke, and D. Barber. 2002. Regulation of erythropoietin-induced STAT serine phosphorylation by distinct mitogen-activated protein kinases. J. Biol. Chem. 277:17359-17366.
13. Kirito, K., T. Nagashima, K. Ozawa, and N. Komatsu. 2002. Constitutive activation of Stat1 and Stat3 in primary erythroleukemia cells. Int. J. Hematol. 75:51-54.[Medline]
14. Kirito, K., K. Nakajima, T. Watanabe, M. Uchida, M. Tanaka, K. Ozawa, and N. Komatsu. 2002. Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation. Blood 99:102-110.
15. Kirito, K., M. Uchida, M. Takatoku, K. Nakajima, T. Hirano, Y. Miura, and N. Komatsu. 1998. A novel function of Stat1 and Stat3 proteins in erythropoietin-induced erythroid differentiation of human leukemia cell line. Blood 92:462-471.
16. Kirito, K., M. Uchida, M. Yamada, Y. Miura, and N. Komatsu. 1997. A distinct function of Stat proteins in erythropoietin signal transduction. J. Biol. Chem. 272:16507-16513.
17. Lenox, L. E., J. M. Perry, and R. F. Paulson. 2005. BMP4 and Madh5 regulate the erythroid response to acute anemia. Blood 105:2741-2748.
18. Li, J., A. D'Andrea, H. Lodish, and D. Baltimore. 1990. Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. Nature 343:762-764.[CrossRef][Medline]
19. Liu, Y., and L. R. Rohrschneider. 2002. The gift of Gab. FEBS Lett. 515:1.[CrossRef][Medline]
20. Million, R. P., N. Harakawa, S. Roumiantsev, L. Varticovski, and R. A. Van Etten. 2004. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol. Cell. Biol. 24:4685-4695.
21. Ney, P., and A. D'Andrea. 2000. Friend erythroleukemia revisited. Blood 96:3675-3680.
22. Ning, Z., J. Li, M. McGuinness, and R. Arceci. 2001. STAT3 activation is required for Asp816 mutant c-Kit induced tumorigenicity. Oncogene 20:4528-4536.[CrossRef][Medline]
23. Nishigaki, K., D. Thompson, C. Hanson, T. Yugawa, and S. Ruscetti. 2001. The envelope glycoprotein of Friend spleen focus-forming virus covalently interacts with and constitutively activates a truncated form of the receptor tyrosine kinase Stk. J. Virol. 75:7893-7903.
24. Ohashi, T., M. Masuda, and S. Ruscetti. 1995. Induction of sequence-specific DNA-binding factors by erythropoietin and the spleen focus-forming virus. Blood 85:1454-1462.
25. Persons, D. A., R. F. Paulson, M. R. Loyd, M. T. Herley, S. M. Bodner, A. Bernstein, P. H. Correll, and P. A. Ney. 1999. Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. Nat. Genet. 23:159.[CrossRef][Medline]
26. Podar, K., G. Mostoslavsky, M. Sattler, Y.-T. Tai, T. Hayashi, L. P. Catley, T. Hideshima, R. C. Mulligan, D. Chauhan, and K. C. Anderson. 2004. Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells. J. Biol. Chem. 279:21658-21665.
27. Ren, Z., and T. S. Schaefer. 2002. ErbB-2 activates Stat3
in a Src- and JAK2-dependent manner. J. Biol. Chem. 277:38486-38493.
28. Sano, S., S. Itami, K. Takeda, M. Tarutani, Y. Yamaguchi, H. Miura, K. Yoshikawa, S. Akira, and J. Takeda. 1999. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 18:4657-4668.[CrossRef][Medline]
29. Sattler, M., M. G. Mohi, Y. B. Pride, L. R. Quinnan, N. A. Malouf, K. Podar, F. Gesbert, H. Iwasaki, S. Li, and R. A. Van Etten. 2002. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1:479.[CrossRef][Medline]
30. Scherr, M., A. Chaturvedi, K. Battmer, I. Dallmann, B. Schultheis, A. Ganser, and M. Eder. 2006. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 107:3279-3287.
31. Subramanian, A., S. Hegde, P. H. Correll, and R. Paulson. 2006. Mutation of the Lyn tyrosine kinase delays the progression of Friend virus induced erythroleukemia without affecting susceptibility. Leuk. Res. 30:1141.[Medline]
32. Subramanian, A., H. E. Teal, P. H. Correll, and R. F. Paulson. 2005. Resistance to Friend virus-induced erythroleukemia in W/Wv mice is caused by a spleen-specific defect which results in a severe reduction in target cells and a lack of Sf-Stk expression. J. Virol. 79:14586-14594.
33. Teal, H., S. Ni, J. Xu, L. Finkelstein, A. Cheng, R. Paulson, G. Feng, and P. Correll. 2006. Grb2-mediated recruitment of Gab2, but not Gab1, to Sf-Stk supports the expansion of Friend virus-infected erythroid progenitor cells. Oncogene 25:2433-2443.[CrossRef][Medline]
34. Teal, H. E., S. Ni, J. Xu, L. D. Finkelstein, A. M. Cheng, R. F. Paulson, G. S. Feng, and P. H. Correll. 2006. GRB2-mediated recruitment of GAB2, but not GAB1, to SF-STK supports the expansion of Friend virus-infected erythroid progenitor cells. Oncogene 25:2433.[CrossRef][Medline]
35. Wang, Y., W. Wharton, R. Garcia, A. Kraker, R. Jove, and W. Pledger. 2000. Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity. Oncogene 19:2075-2085.[CrossRef][Medline]
36. Wiederkehr-Adam, M., P. Ernst, K. Muller, E. Bieck, F. Gombert, J. Ottl, P. Graff, F. Grossmuller, and M. Heim. 2003. Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (Stat1) and Stat3. J. Biol. Chem. 278:16117-16128.
37. Yamamura, Y., H. Senda, Y. Kageyama, T. Matsuzaki, M. Noda, and Y. Ikawa. 1998. Erythropoietin and Friend virus gp55 activate different JAK/STAT pathways through the erythropoietin receptor in erythroid cells. Mol. Cell. Biol. 18:1172-1180.
38. Yu, M., C. A. Lowell, B. G. Neel, and H. Gu. 2006. Scaffolding adapter Grb2-associated binder 2 requires Syk to transmit signals from Fc
RI. J. Immunol. 176:2421-2429.
39. Yu, M., J. Luo, W. Yang, Y. Wang, M. Mizuki, Y. Kanakura, P. Besmer, B. G. Neel, and H. Gu. 2006. The scaffolding adapter Gab2, via SHP-2, regulates Kit-evoked mast cell proliferation by activating the Rac/JNK pathway. J. Biol. Chem. 281:28615-28626.
40. Zhang, J., M. S. Randall, M. R. Loyd, W. Li, R. L. Schweers, D. A. Persons, J. E. Rehg, C. T. Noguchi, J. N. Ihle, and P. A. Ney. 2006. Role of erythropoietin receptor signaling in Friend virus-induced erythroblastosis and polycythemia. Blood 107:73-78.
41. Zhu, Q.-S., L. J. Robinson, V. Roginskaya, and S. J. Corey. 2004. G-CSF-induced tyrosine phosphorylation of Gab2 is Lyn kinase dependent and associated with enhanced Akt and differentiative, not proliferative, responses. Blood 103:3305-3312.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|